Comparative Evaluation of DPP-IV Inhibitors and other Oral Hypoglycaemic Agents used Either Alone or in Combination with Reference to Glycemic Targets in Patients with Type 2 Diabetes Mellitus

Simple item page
dc.contributor.authorMohammad, Anjoomen_US
dc.contributor.authorChand, Miyan Kamaalen_US
dc.contributor.authorBeg, Mirza Atifen_US
dc.contributor.authorBawa, Shaluen_US
dc.date.accessioned2020-09-24T07:10:54Z
dc.date.available2020-09-24T07:10:54Z
dc.date.issued2019-09
dc.description.abstractIntroduction: This study assumes significance as it compareshead on DPP-IV inhibitors along with other oral hypoglycemicagents with respect to glycemic and non-glycemic targets.Study was done to evaluate the DPP-IV inhibitors andother oral hypoglycemic agents (OHA) either alone or incombination, with reference to glycemic targets like fastingplasma glucose (FPG), post prandial glucose (PPG) andglycosylated hemoglobin (HbA1c) in type 2 diabetes mellitus.Material and Methods: This was an open labelledcomparative study and included 90 patients with Type 2 DM.These patients were divided into 3groups: Each group wascontaining 30 patients i.e. Group A: DPP-IV inhibitors (n=30); Group B: Oral hypoglycemic agents other than DPP-IVinhibitors (n= 30) and Group C: DPP-IV inhibitors + other oralhypoglycemic agents (n= 30). The patients were given drugson the basis of physician’s discretion, depending upon theglycemic of the patients at the time of presentation. A detailedhistory regarding age, sex, profession, duration of disease,treatment history, family history and personal history wastaken for each patient. After stabilization patients observed at0 weeks, 6 weeks, 12 weeks and 24 weeks.Results: Mean duration of diabetes was 5.35±0.53 years, andthe mean age of onset of diabetes was 46.98±0.91years. Therewas no significant difference between the study groups withrespect to FPG, PPG, and HbA1c levels. The HbA1c showedsignificant improvement in each group at the end of studyperiod.Conclusion: In summary, this study showed that treatmentwith sitagliptin, either alone or in combination with other oralhypoglycemic agent led to clinically meaningful reductionsin HbA1c, FPG and PPG over a 24 week period. Sitagliptinpresents an alternative therapeutic strategy for patientswith type 2 diabetes and, in general, showed significantimprovements in glycemic control and is well tolerated,particularly with regard to weight change and hypoglycemia.en_US
dc.identifier.affiliationsAssistant Professor, Department of Pharmacology and Therapeutics, Shaikh-Ul-Hind Maulana Mahmood Hasan Medical College, Saharanpur, Uttar Pradeshen_US
dc.identifier.affiliationsAssociate Professor, Department of Pharmacology and Therapeutics, Shaikh-Ul-Hind Maulana Mahmood Hasan Medical College, Saharanpur, Uttar Pradeshen_US
dc.identifier.affiliationsProfessor, Department of Pharmacology, Shri Guru Ram Rai Institute of Medical and Health Sciences, Dehradun Uttarakhanden_US
dc.identifier.affiliationsAssociate Professor, Department of Pharmacology, Shri Guru Ram Rai Institute of Medical and Health Sciences, Dehradun, Uttarakhand, Indiaen_US
dc.identifier.citationMohammad Anjoom, Chand Miyan Kamaal, Beg Mirza Atif, Bawa Shalu. Comparative Evaluation of DPP-IV Inhibitors and other Oral Hypoglycaemic Agents used Either Alone or in Combination with Reference to Glycemic Targets in Patients with Type 2 Diabetes Mellitus. International Journal of Contemporary Medical Research . 2019 Sep; 6(9): i5-i11en_US
dc.identifier.issn2393-915X
dc.identifier.issn2454-7379
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/202549
dc.languageenen_US
dc.publisherInternational Society for Contemporary Medical Researchen_US
dc.relation.issuenumber9en_US
dc.relation.volume6en_US
dc.source.urihttps://dx.doi.org/10.21276/ijcmr.2019.6.9.23en_US
dc.subjectDiabetes Mellitusen_US
dc.subjectOral Hypoglycemic Agentsen_US
dc.subjectPP-IV Inhibitorsen_US
dc.subjectGlycaemic Controlen_US
dc.subjectGlycosylated hemoglobinen_US
dc.titleComparative Evaluation of DPP-IV Inhibitors and other Oral Hypoglycaemic Agents used Either Alone or in Combination with Reference to Glycemic Targets in Patients with Type 2 Diabetes Mellitusen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijcmr2019v6n9pbi5.pdf
Size:
289.2 KB
Format:
Adobe Portable Document Format
Download
Collections
International Journal of Contemporary Medical Research